Fri, March 16, 2018
Thu, March 15, 2018
Wed, March 14, 2018
Tue, March 13, 2018
Mon, March 12, 2018
Fri, March 9, 2018
Thu, March 8, 2018
Wed, March 7, 2018
Tue, March 6, 2018
Mon, March 5, 2018
Fri, March 2, 2018
Thu, March 1, 2018
Wed, February 28, 2018
Tue, February 27, 2018
Mon, February 26, 2018

Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $64 on, Mar 6th, 2018


//stocks-investing.news-articles.net/content/201 .. with-increased-target-to-64-on-mar-6th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $63 to $64 on, Mar 6th, 2018.

Matthew has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Matthew


  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $75 on, Wednesday, February 21st, 2018
  • Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $75 on, Friday, December 1st, 2017

Publication Contributing Sources